Antiplatelet therapy in acute coronary syndromes

被引：4

作者：

Barker C.M. ^{[1
]}

Price M.J. ^{[1
]}

机构：

[1] Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA 92037

来源：

Current Cardiology Reports | 2008年 / 10卷 / 4期

关键词：

Percutaneous Coronary Intervention; Acute Coronary Syndrome; Clopidogrel; Antiplatelet Therapy; Abciximab;

D O I：

10.1007/s11886-008-0052-y

中图分类号：

学科分类号：

摘要：

Acute coronary syndromes (ACS), characterized by unstable angina or a non-ST-segment elevation myocardial infarction, are caused by rupture of an atherosclerotic plaque, leading to platelet activation and aggregation, thrombus formation, and microembolization. Antiplatelet therapy is a cornerstone of therapy. Combined with aspirin, clopidogrel provides significant benefit for patients across the ACS spectrum. However, clopidogrel has limitations given its slow onset and the inconsistent level of inhibition that it achieves. Newer thienopyridine and non-thienopyridine P2Y12 receptor agonists offer the advantages of a rapid onset of action and greater and more consistent platelet inhibition. © Current Medicine Group LLC 2008.

引用

页码：327 / 333

页数：6

共 49 条

[1]

Frelinger A.L., Furman M.I., Linden M.D., Et al., Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: A 700-patient study of aspirin resistance, Circulation, 113, pp. 2888-2896, (2006)

[2]

Cairns J.A., Gent M., Singer J., Et al., Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial, N Engl J Med, 313, pp. 1369-1375, (1985)

[3]

Wallentin L.C., Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden, J Am Coll Cardiol, 18, pp. 1587-1593, (1991)

[4]

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. The Antithrombotic Trialists' Collaboration [no authors listed], BMJ, 324, pp. 71-86, (2002)

[5]

Berger J.S., Stebbins A., Granger C.B., Et al., Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy, Circulation, 117, pp. 192-199, (2008)

[6]

Aleil B., Ravanat C., Cazenave J.P., Et al., Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases, J Thromb Haemost, 3, pp. 85-92, (2005)

[7]

Foster C.J., Prosser D.M., Agans J.M., Et al., Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs, J Clin Invest, 107, pp. 1591-1598, (2001)

[8]

Leon M.B., Baim D.S., Popma J.J., Et al., A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting, N Engl J Med, 339, pp. 1665-1671, (1998)

[9]

Haushofer A., Halbmayer W.M., Prachar H., Neutropenia with ticlopidine plus aspirin, Lancet, 349, pp. 474-475, (1997)

[10]

Campo G., Valgimigli M., Gemmati D., Et al., Poor responsiveness to clopidogrel: Drug-specific or class-effect mechanism?: Evidence from a clopidogrel-to-ticlopidine crossover study, J Am Coll Cardiol, 50, pp. 1132-1137, (2007)

← 1 2 3 4 5 →